Skip to content
Hanmi Pharm
-
Hanmi Pharm licenses obesity drug candidate HM17321 to Roche’s Genentech in US$2.3B deal
Hanmi is developing the HM17321 therapy as a potential first-in-class treatment that could promote weight loss while helping preserve lean body mass.